Company Filing History:
Years Active: 2025
Title: Claudia Noack: Innovator in Antibody Engineering
Introduction
Claudia Noack is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of antibody engineering, particularly through her innovative patent related to Atrial Natriuretic Peptide engrafted antibodies. Her work is vital in advancing therapeutic methods and compositions that utilize these specialized antibodies.
Latest Patents
Claudia Noack holds one patent titled "Atrial natriuretic peptide engrafted antibodies." This invention pertains to an antibody or a fragment that includes at least one heterologous amino acid sequence within its CDR regions. The patent describes the incorporation of an N-terminal linker sequence, an Atrial Natriuretic Peptide (ANP), and a C-terminal linker sequence. Additionally, it outlines the potential for replacing portions of the CDR region with the heterologous amino acid sequence. The invention also covers the use of such antibodies in treatment methods, compositions, nucleic acids encoding the antibodies, host cells containing these nucleic acids, and processes for producing the antibodies.
Career Highlights
Claudia Noack is associated with Bayer Aktiengesellschaft, a leading global company in the pharmaceutical and life sciences sector. Her role at Bayer has allowed her to work on cutting-edge research and development projects that focus on innovative therapeutic solutions.
Collaborations
Claudia collaborates with notable colleagues, including Anke Mayer-Bartschmid and Damian Brockschnieder. These collaborations enhance her research efforts and contribute to the advancement of antibody engineering.
Conclusion
Claudia Noack's contributions to the field of antibody engineering through her innovative patent demonstrate her commitment to advancing medical science. Her work at Bayer Aktiengesellschaft and collaborations with esteemed colleagues further highlight her impact in this vital area of research.